Source: Virtual Congress 2020 – Prevalence and incidence of chronic lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Jakes (Brentford, Middlesex, United Kingdom), N. Kwon (London, United Kingdom), R. Goulding (Boston, United States of America), B. Nordstrom (Boston, United States of America), K. Fahrbach (Boston, United States of America), M. Van Dyke (Collegeville, PA, United States of America). Frequency of eosinophilic granulomatosis with polyangiitis in Europe by meta-analysis. 2592

Member's Comments

No comment yet.

Related content which might interest you: Biologics for eosinophilic granulomatosis with polyangiitis Source: Short video statement 2020 Year: 2020 Eosinophilic granulomatosis with polyangiitis Source: Eur Respir Monogr 2022; 95: 177-192 Year: 2022 Eosinophilic granulomatosis with polyangiitis Source: Eur Respir Monogr 2019; 86: 188-209 Year: 2019 Granulomatosis with polyangiitis (Wegener&s) Source: Eur Respir Mon 2011; 54: 1-14 Year: 2011 Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis Source: ERJ Open Res, 6 (4) 00451-2020; 10.1183/23120541.00451-2020 Year: 2020 Microscopic polyangiitis and granulomatosis with polyangiitis Source: Eur Respir Monogr 2019; 86: 153-172 Year: 2019 New biomarkers for early diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Coexistent granulomatosis with polyangiitis (Wegener‘s) and Crohn disease: A clinicopathologic description of cases Source: Annual Congress 2012 - Pulmonary manifestations of systemic diseases Year: 2012 Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg–Strauss) Source: Eur Respir J 2016; 48: 1429-1441 Year: 2016 Pulmonary hypertension as the first manifestation in a patient with granulomatosis with polyangiitis Source: International Congress 2019 – Pulmonary vascular diseases? Year: 2019 Eosinophilic granulomatosis with polyangiitis (formerly Churg–Strauss syndrome): where are we now? Source: Eur Respir J 2015; 46: 1255-1258 Year: 2015 Different disease subtypes in allergic eosinophilic granulomatosis with polyangiitis (EGPA) Source: Annual Congress 2013 –Clinical management of orphan lung diseases Year: 2013 Lung-limited Granulomatosis with polyangiitis (GPA) managed without immunosuppression Source: International Congress 2018 – CC5 Pulmonary vasculitis: the great chameleon Year: 2018 Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis Source: ERJ Open Res, 6 (1) 00311-2019; 10.1183/23120541.00311-2019 Year: 2020 Secondary organizing pneumonia (BOOP)-associated with granulomatosis with polyangiitis [Wegener granulomatosis (WG)]: A clinicoradiological study of 19 cases Source: International Congress 2014 – ILDs 6 Year: 2014 Wegener granulomatosis : review of 16 cases Source: Eur Respir J 2002; 20: Suppl. 38, 314s Year: 2002 ANCA-negative eosinophilic granulomatosis with polyangiitis (EGPA) relatead to sirolimus-eluting stent Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects Year: 2015 Radiological findings in patients with Wegener granulomatosis Source: Eur Respir J 2003; 22: Suppl. 45, 593s Year: 2003 Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) Source: Eur Respir J, 57 (5) 2004158; 10.1183/13993003.04158-2020 Year: 2021